Since 2015, "Made in China 2025" is accelerating the intelligent transformation of
the manufacturing industry.
In recent years, the state has continued to introduce
relevant guiding policies in the field of intelligent manufacturing.
For example, in September this year, the Ministry of Industry and Information Technology and other four departments jointly issued the Notice on Carrying out Intelligent Manufacturing Pilot Demonstration Actions in 2022, which includes excellent scenarios of intelligent manufacturing and intelligent manufacturing demonstration factories, further promoting the development of
China's intelligent manufacturing industry.
At the end of 2021, the Ministry of Industry and Information Technology and other eight departments issued the "14th Five-Year Plan for Intelligent Manufacturing Development", which clarified how to promote the digitalization and intelligent transformation and upgrading of the manufacturing industry, and put forward the purpose: by 2025, most manufacturing enterprises above designated size will achieve digital networking, and key enterprises in key industries will initially apply intelligence; By 2035, manufacturing enterprises above designated size will fully popularize digital networking, and key enterprises in key industries will basically achieve intelligence
.
With the support of a series of favorable policies, the investment and financing market in the field of intelligent manufacturing has also become more active, which will be conducive to promoting the overall development of
the domestic intelligent manufacturing industry.
On October 24, the 55th and 56th review meetings of the Beijing Stock Exchange in 2022 were held, at which three enterprises including Liaoning Chunguang Pharmaceutical Equipment Co.
, Ltd.
(hereinafter referred to as "Chunguang Pharmaceutical Packaging"), a NEEQ enterprise, passed the meeting
.
It is reported that Chunguang Pharmaceutical is a supplier of highly flexible intelligent packaging equipment, and its main business is the research and development, production and sales of pharmaceutical and
food packaging equipment.
At present, the company's main products include food, pharmaceutical liquid filling equipment, strip bag packaging equipment, aluminum-plastic packaging equipment, automatic cartoning and automatic boxing equipment and other series and highly flexible intelligent packaging linkage production line
.
The sponsor of the Company's offering is China Securities Construction Investment Securities Co.
, Ltd.
According to the prospectus, Chunguang Pharmaceutical intends to issue no more than 25,000,000 shares (without taking into account the over-allotment option); Up to 28.
75 million shares (in the event of full exercise of the over-allotment option of this share offering), the Company and the lead underwriters may choose to adopt the over-allotment option at the option of the specific issuance, and the number of shares issued with the over-allotment option shall not exceed 15% of
the number of shares in this offering.
The company intends to raise about 250 million yuan in the IPO for the construction project of intelligent automation equipment production base and supplementary working capital project
.
The analysis believes that behind Chunguang Pharmaceutical's intention to raise funds to build an intelligent automation equipment production base, or combined with the company's future development strategy and the development trend
of the industry in which it is located.
From the perspective of the industry, it belongs to the packaging equipment industry, the downstream is mainly for the pharmaceutical, food and other industries, in recent years, as far as the single pharmaceutical industry is concerned, with the aging of the population, the continuous upgrading of consumption, and the promotion of medical insurance and other policies, the demand for pharmaceutical market continues to expand, which also brings huge development opportunities
to the pharmaceutical packaging equipment industry.
According to Frost & Sullivan's data, the size of China's pharmaceutical market has increased from 1,329.
4 billion yuan in 2016 to 1,633 billion yuan in 2019, with an average annual compound growth rate of 7.
1%.
This market is expected to reach 2,287.
3 billion yuan
by 2025.
At the same time, the packaging equipment industry is also affected
by pharmaceutical packaging related policies.
On September 8 this year, the Notice on Further Strengthening the Governance of Excessive Packaging of Commodities made relevant provisions on pharmaceutical packaging and specifications, which clearly guided medical institutions to put forward drug packaging specifications for different scenarios and types such as outpatient, inpatient, and chronic diseases, and guided drug manufacturers to optimize drug packaging specifications; Not long ago, Shanghai issued the group standard "Guidelines for Reducing the Dosage of Pharmaceutical Packaging Tablets and Capsules", including clear requirements for the void rate and number of packaging layers of pharmaceutical packaging
.
After the release of these pharmaceutical packaging related requirements and standards, there will be opportunities and challenges for the packaging equipment industry
.
In addition, from the perspective of industry development trends, in recent years, with the rapid development and application of new technologies such as the Internet of Things, artificial intelligence, and 5G, the manufacturing industry, including pharmaceutical packaging equipment, is developing
in the direction of intelligence.
In the context of rising labor costs and accelerated marketing approval of new drugs, pharmaceutical companies have a stronger demand for packaging equipment intelligence and automation in order to control costs and improve the commercialization process of products, forcing packaging equipment companies to increase investment in research and development and accelerate the process
of digital and intelligent transformation.
It is reported that Chunguang Pharmaceutical has established a perfect research and development system, has independently developed and accumulated a number of core technologies, and has formed in-depth industry-university-research cooperation
with some scientific research institutions.
In addition, the company and its chairman and core technician Bi Chunguang participated in the research and drafting
of the recommended national standard formulation plan project of the National Automation System and Integration Standardization Technical Committee "Data Quality Part 62: Data Quality Management: Organizational Process Maturity Assessment: Application of Relevant Standards for Process Evaluation" (National Plan No.
20213014-T604).
It can be seen that the company is striving to grasp the market opportunity
of the rapid development of the intelligent automation equipment industry.
It is expected that after all the proposed fundraising projects are put into operation, it will further optimize the product structure, increase the company's core competitiveness, improve the company's overall efficiency level, promote the company's performance growth, and lay a good foundation
for the company's future development.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize":"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)]; 
